-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
A few days ago, the official website of the State Food and Drug Administration showed that Qilu Pharmaceutical's recombinant human follicle stimulating hormone for injection was approved for marketing.
Since the beginning of this year, Qilu Pharmaceutical has approved 7 injections
.
According to data from Meinenet, the sales of terminal recombinant human follicle stimulating hormone injections in China's public medical institutions have exceeded 1 billion yuan in recent years, with a year-on-year growth of 62.
91% in the first half of 2021
.
Since the beginning of this year, Qilu Pharmaceutical has approved 7 injections
.
According to data from Meinenet, the sales of terminal recombinant human follicle stimulating hormone injections in China's public medical institutions have exceeded 1 billion yuan in recent years, with a year-on-year growth of 62.
91% in the first half of 2021
.
Sales of terminal recombinant human follicle stimulating hormone injections in Chinese public medical institutions in recent years (unit: 100 million yuan)
Source: Mi Nei.
com, China's public medical institutions terminal competition pattern
com, China's public medical institutions terminal competition pattern
Recombinant human follicle stimulating hormone for injection is used to treat infertility
.
According to data from Menet.
com, in recent years , the sales of terminal recombinant human follicle stimulating hormone injections in China's urban public hospitals , county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) have all exceeded 1 billion yuan.
An increase of 62.
91%
.
Prior to this, the only manufacturers of recombinant human follicle stimulating hormone for injection were Merck and Changchun Jinsai Pharmaceutical
.
.
According to data from Menet.
com, in recent years , the sales of terminal recombinant human follicle stimulating hormone injections in China's urban public hospitals , county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) have all exceeded 1 billion yuan.
An increase of 62.
91%
.
Prior to this, the only manufacturers of recombinant human follicle stimulating hormone for injection were Merck and Changchun Jinsai Pharmaceutical
.
Qilu Pharmaceutical said that the recombinant human follicle stimulating hormone for injection is a blockbuster product that has been researched for 11 years.
The approval of the market this time will further increase the availability of the drug and bring high-quality domestic drugs to patients
.
The approval of the market this time will further increase the availability of the drug and bring high-quality domestic drugs to patients
.
Source: Meinenet MED2.
0 Chinese Drug Evaluation Database
0 Chinese Drug Evaluation Database
Since the beginning of this year, Qilu Pharmaceutical has approved 7 injections, among which, Ceftazidime Avibactam Sodium for injection won the first imitation in China
.
From the perspective of the treatment field (big category), it covers systemic anti-infective drugs, anti- tumor and immunomodulators, genitourinary system and sex hormone drugs, cardiovascular system drugs, digestive system and metabolic drugs
.
.
From the perspective of the treatment field (big category), it covers systemic anti-infective drugs, anti- tumor and immunomodulators, genitourinary system and sex hormone drugs, cardiovascular system drugs, digestive system and metabolic drugs
.
Source: official website of the State Food and Drug Administration, Mi Nei.
com database, etc.
com database, etc.
A few days ago, the official website of the State Food and Drug Administration showed that Qilu Pharmaceutical's recombinant human follicle stimulating hormone for injection was approved for marketing.
Since the beginning of this year, Qilu Pharmaceutical has approved 7 injections
.
According to data from Meinenet, the sales of terminal recombinant human follicle stimulating hormone injections in China's public medical institutions have exceeded 1 billion yuan in recent years, with a year-on-year growth of 62.
91% in the first half of 2021
.
Since the beginning of this year, Qilu Pharmaceutical has approved 7 injections
.
According to data from Meinenet, the sales of terminal recombinant human follicle stimulating hormone injections in China's public medical institutions have exceeded 1 billion yuan in recent years, with a year-on-year growth of 62.
91% in the first half of 2021
.
Sales of terminal recombinant human follicle stimulating hormone injections in Chinese public medical institutions in recent years (unit: 100 million yuan)
Source: Mi Nei.
com, China's public medical institutions terminal competition pattern
com, China's public medical institutions terminal competition pattern
Recombinant human follicle stimulating hormone for injection is used to treat infertility
.
According to data from Menet.
com, in recent years , the sales of terminal recombinant human follicle stimulating hormone injections in China's urban public hospitals , county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) have all exceeded 1 billion yuan.
An increase of 62.
91%
.
Prior to this, the only manufacturers of recombinant human follicle stimulating hormone for injection were Merck and Changchun Jinsai Pharmaceutical
.
.
According to data from Menet.
com, in recent years , the sales of terminal recombinant human follicle stimulating hormone injections in China's urban public hospitals , county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) have all exceeded 1 billion yuan.
An increase of 62.
91%
.
Prior to this, the only manufacturers of recombinant human follicle stimulating hormone for injection were Merck and Changchun Jinsai Pharmaceutical
.
Qilu Pharmaceutical said that the recombinant human follicle stimulating hormone for injection is a blockbuster product that has been researched for 11 years.
The approval of the market this time will further increase the availability of the drug and bring high-quality domestic drugs to patients
.
The approval of the market this time will further increase the availability of the drug and bring high-quality domestic drugs to patients
.
Source: Meinenet MED2.
0 Chinese Drug Evaluation Database
0 Chinese Drug Evaluation Database
Since the beginning of this year, Qilu Pharmaceutical has approved 7 injections, among which, Ceftazidime Avibactam Sodium for injection won the first imitation in China
.
From the perspective of the treatment field (big category), it covers systemic anti-infective drugs, anti- tumor and immunomodulators, genitourinary system and sex hormone drugs, cardiovascular system drugs, digestive system and metabolic drugs
.
.
From the perspective of the treatment field (big category), it covers systemic anti-infective drugs, anti- tumor and immunomodulators, genitourinary system and sex hormone drugs, cardiovascular system drugs, digestive system and metabolic drugs
.
Source: official website of the State Food and Drug Administration, Mi Nei.
com database, etc.
com database, etc.
A few days ago, the official website of the State Food and Drug Administration showed that Qilu Pharmaceutical's recombinant human follicle stimulating hormone for injection was approved for marketing.
Since the beginning of this year, Qilu Pharmaceutical has approved 7 injections
.
According to data from Meinenet, the sales of terminal recombinant human follicle stimulating hormone injections in China's public medical institutions have exceeded 1 billion yuan in recent years, with a year-on-year growth of 62.
91% in the first half of 2021
.
Since the beginning of this year, Qilu Pharmaceutical has approved 7 injections
.
According to data from Meinenet, the sales of terminal recombinant human follicle stimulating hormone injections in China's public medical institutions have exceeded 1 billion yuan in recent years, with a year-on-year growth of 62.
91% in the first half of 2021
.
Sales of terminal recombinant human follicle stimulating hormone injections in Chinese public medical institutions in recent years (unit: 100 million yuan)
Source: Mi Nei.
com, China's public medical institutions terminal competition pattern
com, China's public medical institutions terminal competition pattern
Recombinant human follicle stimulating hormone for injection is used to treat infertility
.
According to data from Menet.
com, in recent years , the sales of terminal recombinant human follicle stimulating hormone injections in China's urban public hospitals , county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) have all exceeded 1 billion yuan.
An increase of 62.
91%
.
Prior to this, the only manufacturers of recombinant human follicle stimulating hormone for injection were Merck and Changchun Jinsai Pharmaceutical
.
Hospital hospital hospital.
According to data from Menet.
com, in recent years , the sales of terminal recombinant human follicle stimulating hormone injections in China's urban public hospitals , county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) have all exceeded 1 billion yuan.
An increase of 62.
91%
.
Prior to this, the only manufacturers of recombinant human follicle stimulating hormone for injection were Merck and Changchun Jinsai Pharmaceutical
.
Qilu Pharmaceutical said that the recombinant human follicle stimulating hormone for injection is a blockbuster product that has been researched for 11 years.
The approval of the market this time will further increase the availability of the drug and bring high-quality domestic drugs to patients
.
The approval of the market this time will further increase the availability of the drug and bring high-quality domestic drugs to patients
.
Source: Meinenet MED2.
0 Chinese Drug Evaluation Database
0 Chinese Drug Evaluation Database
Since the beginning of this year, Qilu Pharmaceutical has approved 7 injections, among which, Ceftazidime Avibactam Sodium for injection won the first imitation in China
.
From the perspective of the treatment field (big category), it covers systemic anti-infective drugs, anti- tumor and immunomodulators, genitourinary system and sex hormone drugs, cardiovascular system drugs, digestive system and metabolic drugs
.
Tumor tumor tumor.
From the perspective of the treatment field (big category), it covers systemic anti-infective drugs, anti- tumor and immunomodulators, genitourinary system and sex hormone drugs, cardiovascular system drugs, digestive system and metabolic drugs
.
Source: official website of the State Food and Drug Administration, Mi Nei.
com database, etc.
com database, etc.
